{"protocolSection":{"identificationModule":{"nctId":"NCT00953524","orgStudyIdInfo":{"id":"FUF14"},"secondaryIdInfos":[{"id":"UTN: U1111-1111-4798","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly","officialTitle":"Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects"},"statusModule":{"statusVerifiedDate":"2014-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-08"},"primaryCompletionDateStruct":{"date":"2010-03","type":"ACTUAL"},"completionDateStruct":{"date":"2010-12","type":"ACTUAL"},"studyFirstSubmitDate":"2009-08-03","studyFirstSubmitQcDate":"2009-08-04","studyFirstPostDateStruct":{"date":"2009-08-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-06-08","resultsFirstSubmitQcDate":"2011-06-08","resultsFirstPostDateStruct":{"date":"2011-07-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-02-06","lastUpdatePostDateStruct":{"date":"2014-03-10","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine.\n\nPrimary Objectives:\n\n* To describe the immunogenicity of the candidate vaccines after each injection.\n* To describe the safety of the candidate vaccines after each injection.","detailedDescription":"Participants will receive two injections of their randomized vaccine on Day 0 and Day 21, respectively."},"conditionsModule":{"conditions":["Influenza","Swine-origin A/H1N1 Influenza"],"keywords":["Influenza","Pandemic Flu","Swine-origin A/H1N1 Influenza","Adult"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":849,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A/H1N1 Vaccine Group 1","type":"EXPERIMENTAL","description":"Participants will receive A/H1N1 vaccine formulation 1","interventionNames":["Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)"]},{"label":"A/H1N1 Vaccine Group 2","type":"EXPERIMENTAL","description":"Participants will receive A/H1N1 vaccine formulation 2","interventionNames":["Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)"]},{"label":"A/H1N1 Vaccine Group 3","type":"EXPERIMENTAL","description":"Participants will receive A/H1N1 Vaccine formulation 3","interventionNames":["Biological: Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Participants will receive a placebo vaccine","interventionNames":["Biological: Normal saline solution (placebo)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)","description":"0.5 mL, Intramuscular on Day 0 and on Day 21","armGroupLabels":["A/H1N1 Vaccine Group 1"]},{"type":"BIOLOGICAL","name":"Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)","description":"0.5 mL, Intramuscular on Day 0 and Day 21","armGroupLabels":["A/H1N1 Vaccine Group 2"]},{"type":"BIOLOGICAL","name":"Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)","description":"0.5 mL, Intramuscular on Day 0 and day 21","armGroupLabels":["A/H1N1 Vaccine Group 3"]},{"type":"BIOLOGICAL","name":"Normal saline solution (placebo)","description":"0.5 mL, Intramuscular on Day 0 and Day 21","armGroupLabels":["Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and day 21 post-vaccination"},{"measure":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years","description":"Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination"},{"measure":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination"},{"measure":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1) Strain - Age ≥ 65 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination"},{"measure":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years","description":"Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination"},{"measure":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination"},{"measure":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age 18 to 64 Years","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).","timeFrame":"Days 0 to 7 post-vaccination"},{"measure":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age ≥ 65 Years","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).","timeFrame":"Days 0 to 7 post-vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Healthy adults aged 18 years or older on the day of inclusion\n* Informed consent has been signed and dated\n* Able to attend all scheduled visits and comply with all trial procedures\n* For a woman of child-bearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination, until at least 4 weeks after last vaccination.\n\nExclusion Criteria :\n\n* Known pregnancy or positive urine pregnancy test\n* Currently breastfeeding a child\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Receipt of any vaccine in the 4 weeks preceding the trial vaccination\n* Planned receipt of any vaccine prior to the Day 42 blood sample\n* Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response\n* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Self-reported seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B antigen, or Hepatitis C\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances\n* Self reported thrombocytopenia contraindicating intramuscular (IM) vaccination\n* Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily\n* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures\n* Chronic illness that in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion\n* Employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator.\n* Previous participation in a swine-origin H1N1 pandemic flu trial except if performed in 1976\n* Any confirmed case of influenza (including swine-origin A/H1N1 Influenza) since March 2009\n* Febrile illness (temperature ≥ 100.4°F \\[≥ 38.0°C\\]) or moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination\n* Personal or family history of Guillain-Barré syndrome\n* Active neoplastic disease or a history of any hematologic malignancy\n* Known seizure/epilepsy history and/or taking anti-seizure medication\n* Receipt of psychiatric drugs. Subjects receiving a single antidepressant drug and stable for at least 3 months prior to enrollment, without decompensating symptoms will be allowed to enroll in the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Sanofi Pasteur Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Hoover","state":"Alabama","zip":"35216","country":"United States","geoPoint":{"lat":33.40539,"lon":-86.81138}},{"city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"city":"Phoenix","state":"Arizona","zip":"85020","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"city":"Anaheim","state":"California","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"city":"South Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.7076,"lon":-80.29338}},{"city":"Maddisonville","state":"Kentucky","zip":"42431","country":"United States"},{"city":"Springfield","state":"Missouri","zip":"65802","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"city":"Cincinnati","state":"Ohio","zip":"45227","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"city":"Salt Lake City","state":"Utah","zip":"84124","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"city":"Norfolk","state":"Virginia","zip":"23507","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}}]},"referencesModule":{"references":[{"pmid":"20018365","type":"RESULT","citation":"Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010 Jan 2;375(9708):41-8. doi: 10.1016/S0140-6736(09)62026-2. Epub 2009 Dec 15."}],"seeAlsoLinks":[{"label":"Related Info","url":"http://www.sanofipasteur.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 849 participants who met the inclusion and exclusion criteria were enrolled, vaccinated, and included in data analysis.","recruitmentDetails":"Participants were enrolled from 06 August 2009 to 07 August 2009 at 15 US clinical centers.","groups":[{"id":"FG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"FG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"FG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"FG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"249"},{"groupId":"FG001","numSubjects":"254"},{"groupId":"FG002","numSubjects":"247"},{"groupId":"FG003","numSubjects":"99"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"227"},{"groupId":"FG001","numSubjects":"239"},{"groupId":"FG002","numSubjects":"233"},{"groupId":"FG003","numSubjects":"91"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"14"},{"groupId":"FG003","numSubjects":"8"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"BG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"BG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"BG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"254"},{"groupId":"BG002","value":"247"},{"groupId":"BG003","value":"99"},{"groupId":"BG004","value":"849"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"148"},{"groupId":"BG003","value":"49"},{"groupId":"BG004","value":"499"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"99"},{"groupId":"BG003","value":"50"},{"groupId":"BG004","value":"350"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52.8","spread":"19.2"},{"groupId":"BG001","value":"53.4","spread":"18.9"},{"groupId":"BG002","value":"54.4","spread":"18.4"},{"groupId":"BG003","value":"56.4","spread":"18.1"},{"groupId":"BG004","value":"53.4","spread":"18.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"143"},{"groupId":"BG002","value":"145"},{"groupId":"BG003","value":"57"},{"groupId":"BG004","value":"485"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"102"},{"groupId":"BG003","value":"42"},{"groupId":"BG004","value":"364"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"249"},{"groupId":"BG001","value":"254"},{"groupId":"BG002","value":"247"},{"groupId":"BG003","value":"99"},{"groupId":"BG004","value":"849"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Pre- and post-vaccination antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and day 21 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"45"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) Titers at ≥ 10","categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"61"},{"groupId":"OG003","value":"23"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 10","categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"127"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"21"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 10","categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"22"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years","description":"Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and Day 21 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"45"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) Titers at ≥ 40","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"11"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 40","categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"126"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"10"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 40","categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"127"},{"groupId":"OG002","value":"131"},{"groupId":"OG003","value":"11"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"45"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"11.6","upperLimit":"18.1"},{"groupId":"OG001","value":"17.3","lowerLimit":"13.5","upperLimit":"22.1"},{"groupId":"OG002","value":"14.1","lowerLimit":"11.0","upperLimit":"18.0"},{"groupId":"OG003","value":"14.0","lowerLimit":"9.31","upperLimit":"21.2"}]}]},{"title":"Post-Vaccination 1 (Day 21) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"708","lowerLimit":"555","upperLimit":"903"},{"groupId":"OG001","value":"1362","lowerLimit":"1073","upperLimit":"1729"},{"groupId":"OG002","value":"1526","lowerLimit":"1229","upperLimit":"1895"},{"groupId":"OG003","value":"13.1","lowerLimit":"8.89","upperLimit":"19.3"}]}]},{"title":"Post-Vaccination 2 (Day 42) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"800","lowerLimit":"650","upperLimit":"986"},{"groupId":"OG001","value":"1329","lowerLimit":"1059","upperLimit":"1669"},{"groupId":"OG002","value":"1331","lowerLimit":"1082","upperLimit":"1638"},{"groupId":"OG003","value":"13.5","lowerLimit":"9.23","upperLimit":"19.8"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1) Strain - Age ≥ 65 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Pre- and post-vaccination antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"39"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) Titers at ≥ 10","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"24"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 10","categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"23"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 10","categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"26"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Antibody Titers ≥ 40 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years","description":"Seroprotection: Antibody titer ≥ 40 1/dil. Antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Pre- and post-vaccination antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"39"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) Titers at ≥ 40","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"10"}]}]},{"title":"Post-Vaccination 1 (Day 21) Titers at ≥ 40","categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"80"},{"groupId":"OG003","value":"9"}]}]},{"title":"Post-Vaccination 2 (Day 42) Titers at ≥ 40","categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"10"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMT) of Antibodies Against A/California (H1N1 Vaccine) Strain - Age ≥ 65 Years","description":"Pre-vaccination and post-vaccination antibody titers were determined by the hemagglutination inhibition (HAI) test.","populationDescription":"Antibody titers were assessed in the per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Pre-vaccination (Day 0) and 21 days post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"39"}]}],"classes":[{"title":"Pre-Vaccination 1 (Day 0) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"19.1","lowerLimit":"14.8","upperLimit":"24.5"},{"groupId":"OG001","value":"14.7","lowerLimit":"12.0","upperLimit":"18.1"},{"groupId":"OG002","value":"18.3","lowerLimit":"14.1","upperLimit":"23.7"},{"groupId":"OG003","value":"17.5","lowerLimit":"11.0","upperLimit":"27.9"}]}]},{"title":"Post-Vaccination 1 (Day 21) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"319","lowerLimit":"229","upperLimit":"443"},{"groupId":"OG001","value":"423","lowerLimit":"298","upperLimit":"600"},{"groupId":"OG002","value":"578","lowerLimit":"408","upperLimit":"819"},{"groupId":"OG003","value":"17.5","lowerLimit":"11.2","upperLimit":"27.4"}]}]},{"title":"Post-Vaccination 2 (Day 42) GMT","categories":[{"measurements":[{"groupId":"OG000","value":"359","lowerLimit":"268","upperLimit":"481"},{"groupId":"OG001","value":"416","lowerLimit":"311","upperLimit":"556"},{"groupId":"OG002","value":"604","lowerLimit":"442","upperLimit":"827"},{"groupId":"OG003","value":"19.0","lowerLimit":"12.1","upperLimit":"29.7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age 18 to 64 Years","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).","populationDescription":"Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 0 to 7 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"152"},{"groupId":"OG002","value":"149"},{"groupId":"OG003","value":"49"}]}],"classes":[{"title":"Any Solicited Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"73"},{"groupId":"OG003","value":"9"}]}]},{"title":"Grade 3 Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Pain - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"8"}]}]},{"title":"Any Pain - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"4"}]}]},{"title":"Any Pain - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"72"},{"groupId":"OG003","value":"9"}]}]},{"title":"Grade 3 Pain (Prevents daily activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Erythema - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Erythema - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Erythema - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Grade 3 Erythema (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Swelling - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Swelling - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Swelling - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]},{"title":"Grade 3 Swelling (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Induration - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Induration - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Induration - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Grade 3 Induration (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Ecchymosis - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Grade 3 Ecchymosis (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"24"}]}]},{"title":"Any Grade 3 Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}]},{"title":"Any Fever - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Fever - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Fever - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Grade 3 Fever (≥ 102.1 F or ≥ 39.0 C) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Headache - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"16"}]}]},{"title":"Any Headache - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"11"}]}]},{"title":"Any Headache - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"19"}]}]},{"title":"Grd 3 Headache (Prevents daily activity), Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]},{"title":"Any Malaise - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"9"}]}]},{"title":"Any Malaise - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"6"}]}]},{"title":"Any Malaise - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"13"}]}]},{"title":"Grd 3 Malaise (Prevents daily activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Myalgia - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"11"}]}]},{"title":"Any Myalgia - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"5"}]}]},{"title":"Any Myalgia - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"13"}]}]},{"title":"Grd 3 Myalgia (Prevents daily activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Shivering - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Shivering - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Shivering - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"}]}]},{"title":"Grade 3 Shivering (Prevents activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With At Least One Solicited Injection Site or Systemic Reaction - Age ≥ 65 Years","description":"Solicited Injection Site Reactions: Pain, erythema (redness), swelling, induration (hardening), ecchymosis (bruising). Solicited systemic reactions: Fever (temperature), headache, malaise (feeling unwell), myalgia (muscle aches and pains), shivering (chills).","populationDescription":"Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Days 0 to 7 post-vaccination","groups":[{"id":"OG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively."},{"id":"OG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively."},{"id":"OG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"99"},{"groupId":"OG003","value":"50"}]}],"classes":[{"title":"Any Solicited Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"2"}]}]},{"title":"Grade 3 Injection Site Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Pain - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Pain - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Pain - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"2"}]}]},{"title":"Grade 3 Pain (Prevents daily activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Erythema - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Erythema - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Erythema - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]},{"title":"Grade 3 Erythema (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Swelling - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Swelling - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Swelling - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}]},{"title":"Grade 3 Swelling (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Induration - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Induration - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Induration - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Grade 3 Induration (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Ecchymosis - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Ecchymosis - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Grade 3 Ecchymosis (> 10 cm) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"13"}]}]},{"title":"Any Grade 3 Solicited Systemic Reaction - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Fever - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Fever - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Fever - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"Grade 3 Fever (≥ 102.1 ºF or ≥ 39.0 ºC) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Headache - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"6"}]}]},{"title":"Any Headache - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"}]}]},{"title":"Any Headache - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"11"}]}]},{"title":"Grd 3 Headache (Prevents daily activity), Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Malaise - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"4"}]}]},{"title":"Any Malaise - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"}]}]},{"title":"Any Malaise - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"8"}]}]},{"title":"Grd 3 Malaise (Prevents daily activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Myalgia - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Myalgia - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"5"}]}]},{"title":"Any Myalgia - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"6"}]}]},{"title":"Grd 3 Myalgia (Prevents daily activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Any Shivering - Post Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Any Shivering - Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Any Shivering - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]},{"title":"Grade 3 Shivering (Prevents activity) - Any Dose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events data were collected from the day of vaccination to up to 6 months post-vaccination 2.","eventGroups":[{"id":"EG000","title":"A/H1N1 Vaccine Group 1","description":"Participants who received a dose of A/H1N1 vaccine (7.5 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.","seriousNumAffected":8,"seriousNumAtRisk":248,"otherNumAffected":82,"otherNumAtRisk":248},{"id":"EG001","title":"A/H1N1 Vaccine Group 2","description":"Participants who received a dose of A/H1N1 Vaccine (15 µg hemagglutinin) intramuscularly, on Day 1 and Day 21, respectively.","seriousNumAffected":7,"seriousNumAtRisk":254,"otherNumAffected":78,"otherNumAtRisk":254},{"id":"EG002","title":"A/H1N1 Vaccine Group 3","description":"Participants who received a dose of A/H1N1 Vaccine (30 µg hemagglutinin) intramuscularly on Day 1 and Day 21, respectively.","seriousNumAffected":7,"seriousNumAtRisk":248,"otherNumAffected":96,"otherNumAtRisk":248},{"id":"EG003","title":"Placebo Group","description":"Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively.","seriousNumAffected":4,"seriousNumAtRisk":99,"otherNumAffected":30,"otherNumAtRisk":99}],"seriousEvents":[{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Femoral hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Multiple fractures","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":99}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Lung neoplasm malignan","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Non-Hodgkins lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Oesophageal carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Rectal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Sarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Global amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Myasthenia gravis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":99}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":99}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":254},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":248},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":99}]}],"otherEvents":[{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":82,"numAtRisk":242},{"groupId":"EG001","numAffected":78,"numAtRisk":249},{"groupId":"EG002","numAffected":96,"numAtRisk":246},{"groupId":"EG003","numAffected":11,"numAtRisk":98}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":76,"numAtRisk":242},{"groupId":"EG001","numAffected":68,"numAtRisk":249},{"groupId":"EG002","numAffected":74,"numAtRisk":246},{"groupId":"EG003","numAffected":30,"numAtRisk":99}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":57,"numAtRisk":242},{"groupId":"EG001","numAffected":40,"numAtRisk":249},{"groupId":"EG002","numAffected":63,"numAtRisk":246},{"groupId":"EG003","numAffected":21,"numAtRisk":99}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":242},{"groupId":"EG001","numAffected":50,"numAtRisk":249},{"groupId":"EG002","numAffected":66,"numAtRisk":246},{"groupId":"EG003","numAffected":19,"numAtRisk":99}]},{"term":"Shivering","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":242},{"groupId":"EG001","numAffected":15,"numAtRisk":249},{"groupId":"EG002","numAffected":11,"numAtRisk":246},{"groupId":"EG003","numAffected":5,"numAtRisk":99}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications"},"pointOfContact":{"title":"Medical Director","organization":"Sanofi Pasteur Inc.","email":"RegistryContactUs@sanofipasteur.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}